This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 01
  • /
  • FDA approves Kalydeco (Vertex Pharma) for Cystic F...
Drug news

FDA approves Kalydeco (Vertex Pharma) for Cystic Fibrosis

Read time: 1 mins
Last updated:31st Jan 2012
Published:31st Jan 2012
Source: Pharmawand
The FDA has approved Kalydeco(ivacaftor)from Vertex Pharma, the first medicine to treat the underlying cause of Cystic Fibrosis (CF), a rare, genetic disease. Kalydeco is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Approximately 1,200 people in the United States , or 4 percent of those with CF, are believed to have this mutation. The company has established a financial assistance and patient support program to help get Kalydeco to eligible patients for whom it is prescribed. Kalydeco was discovered as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. , the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.Kalydeco is filed for approval in the EU.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.